Cannabinoid-1 receptor (CB1R) blockers as medicines: Beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists

Expert Opinion on Emerging Drugs

Volumn 17, Issue 1, 2012, Pages 17-29

  Janero, David R ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

brain circuits; drug abuse; drug targeting; endocannabinoid signaling system; G protein coupled receptor; gastrointestinal motility; hepatic steatosis; metabolic syndrome; psychobehavioral disturbance; side effects

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; MESSENGER RNA; NEUROTRANSMITTER; OTENABANT; RIMONABANT; SURINABANT; TARANABANT;

BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG RESPONSE; HUMAN; NAUSEA; NONHUMAN; OBESITY; REWARD; SHORT SURVEY; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ENDOCANNABINOIDS; HEART DISEASES; HUMANS; MOLECULAR STRUCTURE; OBESITY; PHARMACEUTICAL PREPARATIONS; RECEPTOR, CANNABINOID, CB1; SUBSTANCE-RELATED DISORDERS;

EID: 84858990388     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.660916     Document Type: Short Survey

References (127)

1. Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 2009;14:43-65
2. Janero DR, Lindsley L, Vemuri VK, Makriyannis A. Cannabinoid 1 G protein-coupled receptor (periphero-) neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. Expert Opin Drug Discov 2011;6:995-1025 Comprehensive review and analysis of different pharmacological classes of CB1R blockers as related to obesity and cardiometabolic indications.
3. Kunos G, Tam J. The case for peripheral CB1 receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 2011;163:1423-31
4. Wu Y-K, Yeh C-F, Ly TW, Hung M-S. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier. Curr Top Med Chem 2011;11:1421-9 Discussion of the pharmacology and design of peripherally biased CB1R inverse agonists.
5. Ward SJ, Raffa RB. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/ inverse-agonist therapies. Obesity 2011;19:1325-34
6. Lopez-Moreno JA, Gonzales-Cuevas G, Moreno G, Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol 2008;13:160-87 (Pubitemid 351692981)
7. Solinas M, Goldberg SR, Piomelli D. The endocananbinoid system in brain reward processes. Br J Pharmacol 2008;154:369-83 (Pubitemid 351670594)
8. Fattore L, Melis M, Fadda P, et al. The endocananbinoid system and nondrug rewarding behaviours. Exp Neurol 2010;224:23-6
9. Kenny PJ. Common cellular and molecular mechanisms in obesity and drug addiction. Nat Rev Neurosci 2011;12:638-51 Neurobiological and behavioral overview of the common pathological underpinnings of obesity and drug addiction as substance abuse disorders.
10. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011;published online 12 December 2010; doi:10.1155/2011/179674
11. Jupp B, Lawrence AJ. New horizons for therapeutics in drug and alcohol abuse. Pharmacol Ther 2010;125:138-68
12. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Can Med Assoc J 2011;183:1359-408
13. Bond RA, Ijzerman AP. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006;27:92-6 (Pubitemid 43184030)
14. Smith NJ, Bennett KA, Milligan G. When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 2011;331:241-7
15. Atwood BK, Wagner-Miller J, Haskins C, et al. Functional selectivity in CB2 cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB2 ligands. Mol Pharmacol 2012;81:250-63
16. Janero DR, Makriyannis A. Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity. Curr Psychiatry Rep 2007;9:365-73 (Pubitemid 47559357)
17. Bosier B, Muccioli GG, Hermans E, Lambert DM. Functionally selective cannabinoid receptor signaling: therapeutic implications and opportunities. Biochem Pharmacol 2010;80:1-12
18. 7TM Pharma. Press release. 7TM Pharma successfully conducts Phase I trial of its first in class peripheral CB1 receptor antagonist TM38837 demonstrating restriction from the human CNS. Available from: http:// ww.7tm.dk/News.aspx? M=News&PID=5&NewsID=58 [Last accessed 20 January 2012]
19. Cluny NL, Chambers AP, Vemuri VK, et al. The neutral cannabinoid CB1 receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 2011;97:537-43
20. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120:2953-66
21. Vilardaga JP. Theme and variations on kinetics of GPCR activation/deactivation. J Recept Signal Transduct Res 2010;30:304-12
22. Giraldo J. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. Drug Discov Today 2010;15:411-15 Discussion of the molecular pharmacology of GPCR antagonists along a continuum of inverse-agonist and neutral modes of action.
23. Howlett AC, Reggio PH, Childers SR, et al. Endocannaibnoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol 2011;163:1329-43
24. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005;76:1307-24
25. Sim-Selley LJ, Brunk LK, Selley DE. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 2001;414:135-43 (Pubitemid 32181880)
26. Erdozain AM, DIez-Alarcia R, Meana JJ, Callado LF. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from post mortem human brain. Biochem Pharmacol 2011;83:260-8
27. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009;60:77-84 General overview of the endocannabinoid signaling system.
28. Pertwee RG, Howlett AC, Abood ME, et al. International union of basic and clinical pharmacology. LXXIX.Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010;62:588-631
29. Lopez-Moreno JA, Lopez-Jimenez A, Gorriti MA, Rodriguez de Fonseca F. Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets 2010;11:406-28
30. Hill MN, Patel S, Campolongo P, et al. Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci 2010;30:14980-6
31. Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol 2008;88:335-69
32. Rinaldi-Carmona M, Pialot F, Cogny C, et al. Characterization and distribution of binding sites for [3H]-SR141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci 1996;58:1239-47 (Pubitemid 26096331)
33. Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 2011;published online 29 April 2011; doi:10.1177/1073858410397377 Review integrating endocannabinoid system function in the control of neurotransmitter release and CNS signaling.
34. Chiu CQ, Puente N, Grandes P, Castillo PE. Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci 2010;30:7236-48
35. Przbyla JA, Watts VJ. Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor herterodimers. J Pharmacol Exp Ther 2010;332:710-19
36. Gonzalez S, Cascio MG, Fernandez-Ruiz J, et al. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002;954:73-81 (Pubitemid 35223443)
37. Gonzalez S, Fernandez-Ruiz J, Sparpaglione V, et al. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend 2002;66:77-84 (Pubitemid 34159259)
38. Bortolato M, Frau R, Bini V, et al. Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB1 cannabinoid receptors. J Psychiatr Res 2010;44:944-55
39. Hirvonen J, Goodwin RS, Li CT, et al. Reversible and regionally selective downregulation of brain cannabinoid CB (1) receptors in chronic daily cannabis smokers. Mol Psychiatry 2011;published online 12 July 2011; doi:10.1308/mp.2011. 82
40. Zhang PW, Ishiguro H, Ohtsuki T, et al. Human cannabinoid receptor 1:5 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004;9:916-31 (Pubitemid 39381956)
41. Chen X, Williamson VS, An SS, et al. Cannabinoid receptor 1 gene association with nicotine dependence. Arch Gen Psychiatry 2008;65:816-24 (Pubitemid 351957707)
42. Proudnikov D, Kroslak T, Sipe JC, et al. Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1. Pharmacogenomics J 2010;10:232-42
43. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonesca F. The endocananbinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 2010;95:375-82
44. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011;5:1-8
45. Manzanedo C, Aguilar MA, Rodriguez-Arias M, et al. Cannabinoid agonist-induced sensitization to morphine place preference in mice. Neuroreport 2004;15:1371-7
46. Solinas M, Panlilio LV, Tanda G, et al. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 2005;30:2046-57 (Pubitemid 43093504)
47. Gonzalez-Cuevas G, Aujla H, Martin-Fardon R, et al. Subchronic cannabinoid agonist (WIN 55,212-2) treatment during cocaine abstinence alters subsequent cocaine seeking behavior. Neuropsychopharmacology 2007;32:2260-6 (Pubitemid 47587677)
48. Malinen H, Hyytia P. Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats. Alcohol Clin Exp Res 2008;32:1976-83
49. Manzanedo C, Rodriguez-Arias M, Daza-Losada M, et al. Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice. Behav Brain Funct 2010;published online 22 March 2010; doi:10.1186/1744-9081-6-19
50. Gamaleddin I, Wertheim C, Zhu AZ, et al. Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addict Biol 2011;published online 26 April 2011; doi:10.1111/j.1369-1600.2011.00314x
51. McLaughlin PJ, Qian L, Wood JT, et al. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav 2006;83:396-402 (Pubitemid 43736963)
52. Droste SM, Saland SK, Schlitter EK, Rodefer JS. AM 251 differentially effects food-maintained responding depending on food palatability. Pharmacol Biochem Behav 2010;95:443-8
53. Wagner JD, Zhang L, Kavanagh K, et al. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys. J Pharmacol Exp Ther 2010;335:103-13
54. Fong TM, Guan X-M, Marsh DJ, et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl- 2-{[5-(trifluoromethyl)pyridine-2-yl]oxy} propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 2007;321:1013-22 (Pubitemid 46762708)
55. Solinas M, Panlilo LV, Antoniou K, et al. The cannabinoid CB1 antagonistN-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4- methylpyrazole-3- carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedule of drug self-administration in rats. J Pharmacol Exp Ther 2003;306:93-102 (Pubitemid 36734361)
56. Xi ZX, Gilbert JG, Peng XQ, et al. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. J Neurosci 2006;26:8531-6 (Pubitemid 44316182)
57. Azizi P, Haghparast A, Hassanpour-Ezatti M. Effects of CB1 receptor antagonist within the nucleus accumbens on the acquisition and expression of morphine-induced conditioned place preference in morphine-sensitized rats. Behav Brain Res 2009;197:119-24
58. de Bruin NM, Lange JH, Kruse CG, et al. SLV330, a cannabinoid CB(1) receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behav Brain Res 2011;217:408-15
59. Daza-Losada M, Minarro J, Aguilar MA, et al. Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference. Pharmacol Biochem Behav 2011;100:33-9
60. Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs 2006;66:2109-19 (Pubitemid 46372361)
61. Hagmann WK. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity. Arch Pharm 2008;341:405-11
62. Lange JH, van der Neut MA, den Hartog AP, et al. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists. Bioorg Med Chem Lett 2010;20:1752-7
63. Lamota L, Bermudez-Silva FJ, Marco EM, et al. Effects of adolescent nicotine and SR 147778 (surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology 2008;54:194-205 (Pubitemid 350299415)
64. Scheen AJ. CB1 Receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO program with rimonabant. J Neuroendocrinol 2008;20:S139-46
65. Despres JP. Pleiotropic effects of rimonabant: clinical implications. Curr Pharm Des 2009;15:553-70
66. Kipnes MS, Hollander P, Fujioka K, et al. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obes Metab 2010;12:517-31
67. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 2011;36:10-18
68. Aronne LJ, Finer N, Hollander PA, et al. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity 2011;19:1404-14
69. Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011;published online 24 January 2011; doi:10.1002/14651858.CD005353.pub4
70. Wilcox CS, Noble EP, Oskooilar N. ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. J Investig Med 2011;published online 12 October 2011; doi:10.231/JIM. 0b013e31823581fa
71. Soyka M, Koller G, Schmidt P, et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol 2008;28:317-24
72. Morrison MF, Ceesay P, Gantz I, et al. Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology (Berl) 2010;209:245-53
73. Aronne LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes 2010;34:919-35
74. Proietto J, Rissanen A, Harp JB, et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes 2010;34:1243-54
75. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 2008;7:961-6
76. Fong TM, Heymsfield SB. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int J Obes 2009;33:947-55
77. Martin-Garcia E, Burokas A, Martin M, et al. Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant. J Neurochem 2010;112:1338-51
78. Moriera FA, Grieb M, Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 2009;23:133-44
79. Maccioni P, Colombo G, Carai MA. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data. CNS Neurol Disord Drug Targets 2010;9:55-9
80. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid- oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009;205:171-4
81. Valverde O. Participation of the endocannabinoid system in the regulation of emotional-like behavior. Curr Pharm Des 2005;11:3241-9
82. Hill MN, Gorzalka BB. Impairments in endocananbinoid signaling and depressive illness. JAMA 2009;301:1165-6
83. Arevalo C, de Miguel R, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviors and hypothalamic neurotransmitters. Pharmacol Biochem Behav 2001;70:123-31 (Pubitemid 32786974)
84. Gribel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005;57:261-7 (Pubitemid 40187370)
85. Thiemann G, Watt CA, Ledent C, et al. Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain. Behav Brain Res 2009;200:67
86. Martin-Garcia E, Burokas A, Martin M, et al. Central and peripheralconsequences of the chronic blockade of CB1 receptor with rimonabant or taranabant. J Neurochem 2010;112:1138-51 Discussion of various CNS-related and peripheral adverse events associated with typical CB1R inverse agonists.
87. Aso A, Ozaita A, Serra MA, Maldonado R. Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype. Eur Neuropsychopharmacol 2011;21:11-22
88. Receveur J-M, Murray A, Linget J-M, et al. Conversion of 4-cyanomethylpyrazole- 3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain barrier. Bioorg Med Chem Lett 2010;20:453-7
89. Hortala L, Rinaldi-Carmona M, Congy C, et al. Rational design of a novel peripherally-restricted, orally active CB1 cannabinoid antagonist containing a 2,3-diarylpyrrole motif. Bioorg Med Chem Lett 2010;20:4573-7
90. Hung M-S, Chang C-P, Li T-C, et al. Discovery of 1-(2,4-dichlorophenyl)- 4- ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl) ethynyl)thiophen-2-yl)-N- (piperidin-1- yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist. Chem Med Chem 2010;5:1439-43
91. Bermudez-Silva FJ, Cardinal P, Cota D. The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 2011;published online 8 August 2011; doi:10.1177/0269881111408458
92. Quarta C, Mazza R, Obici S, et al. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 2011;17:518-26
93. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1:223-36 (Pubitemid 44244128)
94. Gifford AN, Bruneus M, Gatley SJ, et al. Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 1999;288:478-83 (Pubitemid 29119654)
95. Addy C, Wright H, Van Laere K, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008;7:68-78
96. Borisenko SA. Effects of drugs on blood-brain barrier permeability in rats chronically intoxicated by ethanol. Ann Ist Super Sanita 1990;26:39-42 (Pubitemid 20273152)
97. Lossinsky AS, Shivers RR. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol Histopathol 2004;19:535-64 (Pubitemid 38450634)
98. Sharma HS, Ali SF. Alterations in blood-brain barrier function by morphine and methamphetamine. Ann N Y Acad Sci 2006;1074:198-224 (Pubitemid 44532825)
99. Dietrich JB. Alteration of blood-brain barrier function by methamphetamine and cocaine. Cell Tissue Res 2009;336:385-92
100. Sharma HS, Sjoquist PO, Ali SF. Alterations in blood-brain barrier function and brain pathology by morphine in the rat. Neuroprotective effects of antioxidant H-290/51. Acta Neurochir 2010;106:S61-6
101. Izzo AA, Mascolo N, Borrelli F, Capasso F. Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedberg's Arch Pharmacol 1999;359:65-70 (Pubitemid 29142572)
102. Lehmann A, Blackshaw LA, Branden L, et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002;123:1129-34
103. Storr MA, Bashasati M, Hirota C, et al. Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice. Neurogastroenterol Motil 2010;22:787-97 Direct preclinical demonstration that CB1R neutral antagonists are devoid of peripheral (GI) adverse events associated with CB1R inverse agonists.
104. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010;126:21-38 Overview of the critical role of cannabinergic signaling in GI system homeostasis and health.
105. Chambers AP, Vemuri VK, Peng Y, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 2007;293:R2185-93 (Pubitemid 350224010)
106. Fride E, Braun H, Matan H, et al. Inhibition of milk ingestion and growth after administration of a neutral acannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Pediatr Res 2007;62:533-6 (Pubitemid 351338985)
107. Salamone JD, McLaughlin PJ, Sink K, et al. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007;91:383-8 (Pubitemid 47016540)
108. Sink KS, McLaughlin PJ, Wood JA, et al. The novel cannabinoid CB1R receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008;33:946-55 (Pubitemid 351252707)
109. Bostrom J, Olsson RI, Tholander J, et al. Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorg Med Chem Lett 2010;20:479-82
110. Lin Y, Shia K-S, Hsiao W-C, et al. Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities. Pharmacol Res 2010;62:337-43
111. Cluny NL, Chambers AP, Vemuri VK, et al. The neutral cannabinoid CB(1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 2011;97:537-43
112. Lafenetre P, Chaouloff F, Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 recpetors may modulate fear extinction. Pharmacol Res 2007;56:367-81 (Pubitemid 350026395)
113. Finn DP. Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiology 2010;215:629-46
114. Riebe CJ, Wotjak CT. Endocannabinoids and stress. Stress 2011;14:384-97
115. Das UN. Obesity: genes, brain, gut, and environment. Nutrition 2010;26:459-73
116. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-5
117. Kirilly E, Gonda X, Bagdy G. CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol 2011;published online 26 December 2011; doi:10.1111/j.1748- 1716.2011.02402.x
118. Panagis G, Vlachou S, Nomikos GG. Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Curr Drug Abuse Rev 2008;1:350-74
119. Panlilio LV, Justinova Z, Goldberg SR. Animal models of cannabinoid reward. Br J Pharmacol 2010;160:499-510
120. Stewart A, Wong K, Cachat J, et al. Zebrafish models to study drug abuse-related phenotypes. Rev Neurosci 2011;22:95-105
121. Fernando AB, Robbins TW. Animal models of neuropsychiatric disorders. Annu Rev Clin Psychol 2011;7:39-61
122. Horswill JG, Bali U, Shaaban S, et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 2007;152:805-14 (Pubitemid 350034966)
123. Smith TH, Sim-Selley LJ, Selley DE. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 2010;160:454-66
124. Xi Z-X, Peng X-Q, Li X, et al. Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat Neurosci 2011;14:1160-8
125. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001;60:155-63 (Pubitemid 32595243)
126. Cinar R, Szucs M. CB1 receptor-independent actions of SR 141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells. J Pharmacol Exp Ther 2009;330:567-74
127. Mellman I, Nussenzweig M. Retrospective. Ralph M. Steinman (1943-2011). Science 2011;334:466